No quarterly revenue total was found in Quince Therapeutics, Inc.'s SEC filings.
Quince Therapeutics, Inc. (IRLA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$18.9 million. As of Jun 30, 2026 it held $116.0 million in cash and investments and $0 in total debt.
Revenue
—
Net income
$-75.49M
-370.4% vs year-ago quarter
Operating cash flow
$-18.89M
-65.5% vs year-ago quarter
Free cash flow
$-18.89M
-63.7% vs year-ago quarter
EPS
$-12.31
+82.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.02M
-98.1% vs year-ago quarter
Net cash
$115.98M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IRLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1662774
- Former names
- Quince Therapeutics, Inc. (until Oct 9, 2026); Cortexyme, Inc. (until Aug 1, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$79.8M | -$14.6M | -$19.4M | -$13.4M | -$10.4M |
| Net income | -$75.5M | $35.9M | -$39.5M | -$13.4M | -$16.0M |
| Diluted EPS | -$12.31 | $2.88 | -$0.71 | -$0.25 | -$68.75 |
| Operating cash flow | -$18.9M | -$7.6M | -$10.5M | -$9.9M | -$11.4M |
| Free cash flow | -$18.9M | -$7.6M | -$10.5M | -$10.0M | -$11.5M |
| Total assets | $124.0M | $26.6M | $93.5M | $109.9M | $117.2M |
| Total liabilities | $15.5M | $11.0M | $129.2M | $108.8M | $105.5M |
| Stockholders' equity | -$35.3M | $15.7M | -$35.7M | $1.1M | $11.7M |
| Cash and investments | $116.0M | $18.2M | $5.8M | $6.5M | $16.8M |
| Total debt | $0 | $406,000 | $18.5M | $18.0M | $17.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Oct 9, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Officer or director change
|
Sep 14, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 4, 2026 | Aug 31, 2026 |
All 462 Quince Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.